Moleculin Biotech, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Jonathan P. Foster, Moleculin Biotech's CFO, has increased his beneficial ownership to 6.3% through recent purchases and exercisable warrants, signaling active investment and potential influence.
NASDAQ
SCHEDULE: CEO Klemp Boosts Moleculin Stake to 9.9%
Walter V. Klemp, CEO and Chairman of Moleculin Biotech, Inc., has increased his beneficial ownership to 9.9% through a recent public offering purchase and existing warrants and options.